Skip to main content
editorial
. 2022 Feb 4;16(1):1–23. doi: 10.1007/s12072-021-10276-6

Fig. 4.

Fig. 4

Risk-based approach for PBC patients. UDCA ursodeoxycholic acids, OCA Obeticholic acid